Hudson Bay Capital Management
BBIO icon

Hudson Bay Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Hudson Bay Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-100,000
Closed -$3.46M – 1386
2025
Q1 		$3.46M Buy
+100,000
New +$3.37M 0.01% 694

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Hudson Bay Capital Management's BBIO Position: Q2 2026 in Review

Hudson Bay Capital Management opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 25,860 shares worth $1.93M. The stake represents 0.01% of the portfolio and ranks #827 among its holdings. This is a return to the name: Hudson Bay Capital Management previously reported a position in BBIO as recently as Q1 2025.

Hudson Bay Capital Management first reported a position in BBIO in Q2 2020 and has held it in 10 quarters since. The position peaked at $5.19M in Q1 2025. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Hudson Bay Capital Management held 25,860 shares of BridgeBio Pharma worth $1.93M as of Q2 2026.
  • BridgeBio Pharma was a new Hudson Bay Capital Management position in Q2 2026.
  • BridgeBio Pharma made up 0.01% of Hudson Bay Capital Management's portfolio in Q2 2026, its #827 holding.
  • Hudson Bay Capital Management first reported a position in BridgeBio Pharma in Q2 2020 and has held it in 10 quarters since.
  • Hudson Bay Capital Management's BridgeBio Pharma position peaked at $5.19M in Q1 2025.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.